nach oben

Erschienen in:

07.03.2019 | Diabetes und Herz | Schwerpunkt

Mikrobiom, Diabetes und Herz: neue Zusammenhänge?

verfasst von: Dr. Dr. med. B. A. Kappel, Prof. Dr. med. M. Lehrke

Erschienen in: Herz | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Patienten mit Typ-2-Diabetes haben ein hohes kardiovaskuläres Risiko. Die zugrunde liegenden Pathomechanismen sind bisher nicht hinreichend verstanden und die therapeutischen Möglichkeiten dementsprechend begrenzt. Das Darmmikrobiom könnte eine wichtige Rolle bei kardiometabolischen Erkrankungen spielen. Ein Ungleichgewicht in der Darmflora wurde bereits mit Insulinresistenz, Diabetes mellitus und kardiovaskulären Erkrankungen wie Atherosklerose und Herzinsuffizienz in Verbindung gebracht. Ein Teil der negativen kardiovaskulären Effekte des Typ-2-Diabetes mellitus könnte somit über die intestinale Bakterienflora vermittelt werden. Dieser Übersichtsartikel diskutiert spezifische, mit dem Darmmikrobiom assoziierte Mechanismen, welche sowohl beim Typ-2-Diabetes als auch bei Herz-Kreislauf-Erkrankungen moduliert sind. Auf der einen Seite wird dargestellt, wie Darmbakterien zu einer systemischen Low-grade-Inflammation beitragen können. Auf der anderen Seite wird aufgezeigt, wie das intestinale Mikrobiom als komplexes metabolisches Organ über die Produktion von bioaktiven Metaboliten den kardiometabolischen Phänotyp beeinflusst. Weitere Studien müssen zeigen, ob diese Mechanismen zu dem hohen kardiovaskulären Risiko bei Typ-2-Diabetes beitragen.

Askoxylakis V et al (2010) Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer 10:105. https://doi.org/10.1186/1471-2407-10-105 CrossRefPubMedPubMedCentral

Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution. Eur J Heart Fail 18:891–975. https://doi.org/10.1093/eurheartj/ehw128 CrossRefPubMed

Bahtiyar G, Gutterman D, Lebovitz H (2016) Heart failure: a major cardiovascular complication of diabetes mellitus. Curr Diab Rep. https://doi.org/10.1007/s11892-016-0809-4 CrossRefPubMedPubMedCentral

Kappel B, Marx N, Federici M (2015) Oral hypoglycemic agents and the heart failure conundrum: lessons from and for outcome trials. Nutr Metab Cardiovasc Dis 25:697–705. https://doi.org/10.1016/j.numecd.2015.06.006 CrossRefPubMed

Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720 CrossRefPubMed

Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657. https://doi.org/10.1056/NEJMoa1611925 CrossRefPubMed

Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322. https://doi.org/10.1056/NEJMoa1603827 CrossRefPubMedPubMedCentral

Nicholson J, Holmes E, Kinross J et al (2012) Host-gut microbiota metabolic interactions. Science 336(6086):1262–1267. https://doi.org/10.1126/science.1223813 CrossRefPubMed

Sender R, Fuchs S, Milo R (2016) Revised estimates for the number of human and bacteria cells in the body. Plos Biol. https://doi.org/10.1371/journal.pbio.1002533 CrossRefPubMedPubMedCentral

10.

Turnbaugh PJ et al (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027–1031. https://doi.org/10.1038/nature05414 CrossRefPubMed

11.

Ridaura VK, Faith JJ, Rey FE et al (2013) Gut microbiota from twins discordant for obesity modulate metabolism in mice gut microbiota from twins metabolism in mice. Science 341:1241214. https://doi.org/10.1126/science.1241214 CrossRefPubMed

12.

Frank DN, Pace NR (2008) Gastrointestinal microbiology enters the metagenomics era. Curr Opin Gastroenterol 24:4–10. https://doi.org/10.1097/MOG.0b013e3282f2b0e8 CrossRefPubMed

13.

Qin J, Li R, Raes J et al (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464:59–65. https://doi.org/10.1038/nature08821 CrossRefPubMedPubMedCentral

14.

Murgas Torrazza R, Neu J (2011) The developing intestinal microbiome and its relationship to health and disease in the neonate. J Perinatol 31(Suppl 1):S29–S34. https://doi.org/10.1038/jp.2010.172 CrossRefPubMed

15.

Nicholson JK, Wilson ID (2003) Opinion: understanding „global“ systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov 2:668–676. https://doi.org/10.1038/nrd1157 CrossRefPubMed

16.

Karlsson FH, Fåk F, Nookaew I et al (2012) Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun 3. https://doi.org/10.1038/ncomms2266 CrossRefPubMed

17.

Jie Z, Xia H, Zhong S‑L et al (2017) The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun 8:845. https://doi.org/10.1038/s41467-017-00900-1 CrossRefPubMedPubMedCentral

18.

Hoyles L et al (2018) Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med. https://doi.org/10.1038/s41591-018-0061-3 CrossRefPubMedPubMedCentral

19.

Le Chatelier E, Nielsen T, Qin J et al (2013) Richness of human gut microbiome correlates with metabolic markers. Nature 500:541–546. https://doi.org/10.1038/nature12506 CrossRefPubMed

20.

Pedersen HK et al (2016) Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 535:376–381. https://doi.org/10.1038/nature18646 CrossRefPubMed

21.

Wang Z, Klipfell E, Bennett BJ et al (2011) Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472:57–63. https://doi.org/10.1038/nature09922 CrossRefPubMedPubMedCentral

22.

Henao-Mejia J, Elinav E, Jin C et al (2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482:179–185. https://doi.org/10.1038/nature10809 CrossRefPubMedPubMedCentral

23.

Suez J, Korem T, Zeevi D et al (2014) Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature 514:181–186. https://doi.org/10.1038/nature13793 CrossRefPubMed

24.

Blandino G et al (2016) Impact of gut microbiota on diabetes mellitus. Diabetes Metab. https://doi.org/10.1016/j.diabet.2016.04.004 CrossRefPubMed

25.

Frank DN, Amand ALS, Feldman RA et al (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104:13780–13785. https://doi.org/10.1073/pnas.0706625104 CrossRefPubMedPubMedCentral

26.

Bartolomaeus H et al (2018) The short-chain fatty acid propionate protects from hypertensive cardiovascular damage. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.118.036652 CrossRefPubMedCentral

27.

Goldsmith JR, Sartor RB (2014) The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. J Gastroenterol 49:785–798. https://doi.org/10.1007/s00535-014-0953-z CrossRefPubMedPubMedCentral

28.

Karmarkar D, Rock KL (2013) Microbiota signalling through MyD88 is necessary for a systemic neutrophilic inflammatory response. Immunology 140:483–492. https://doi.org/10.1111/imm.12159 CrossRefPubMedPubMedCentral

29.

Parrinello CM, Lutsey PL, Ballantyne CM et al (2015) Six-year change in high-sensitivity C‑reactive protein and risk of diabetes, cardiovascular disease, and mortality. Am Heart J 170:380–389.e4. https://doi.org/10.1016/j.ahj.2015.04.017 CrossRefPubMedPubMedCentral

30.

Ridker PM, Everett BM, Thuren T et al (2017) Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131. https://doi.org/10.1056/NEJMoa1707914 CrossRefPubMed

31.

Lepper PM, Kleber ME, Grammer TB et al (2011) Lipopolysaccharide-binding protein (LBP) is associated with total and cardiovascular mortality in individuals with or without stable coronary artery disease--results from the Ludwigshafen Risk and Cardiovascular Health Study (LURIC). Atherosclerosis 219:291–297. https://doi.org/10.1016/j.atherosclerosis.2011.06.001 CrossRefPubMed

32.

Krogh-Madsen R et al (2008) Effect of short-term intralipid infusion on the immune response during low-dose endotoxemia in humans. Am J Physiol Endocrinol Metab. https://doi.org/10.1152/ajpendo.00507.2007 CrossRefPubMed

33.

Gnauck A, Lentle RG, Kruger MC (2016) The characteristics and function of bacterial lipopolysaccharides and their endotoxic potential in humans. Int Rev Immunol 35(3):189–218CrossRefPubMed

34.

Cani PD, Amar J, Iglesias MA et al (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:1761–1772. https://doi.org/10.2337/db06-1491 CrossRefPubMed

35.

Wiedermann CJ et al (1999) Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol. https://doi.org/10.1016/S0735-1097(99)00448-9 CrossRefPubMed

36.

Pussinen PJ, Tuomisto K, Jousilahti P et al (2007) Endotoxemia, immune response to periodontal pathogens, and systemic inflammation associate with incident cardiovascular disease events. Arterioscler Thromb Vasc Biol. https://doi.org/10.1161/ATVBAHA.106.138743 CrossRefPubMed

37.

Szeto CC et al (2008) Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol. https://doi.org/10.2215/CJN.03600807 CrossRefPubMedPubMedCentral

38.

Creely SJ, McTernan PG, Kusminski CM et al (2006) Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. https://doi.org/10.1152/ajpendo.00302.2006 CrossRefPubMed

39.

Pussinen PJ et al (2011) Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care. https://doi.org/10.2337/dc10-1676 CrossRefPubMedPubMedCentral

40.

Cuaz-Pérolin C, Billiet L, Baugé E et al (2008) Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-beta-boswellic acid in LPS-challenged ApoE-/- mice. Arterioscler Thromb Vasc Biol. https://doi.org/10.1161/ATVBAHA.107.155606 CrossRefPubMed

41.

Malik TH, Cortini A, Carassiti D et al (2010) The alternative pathway is critical for pathogenic complement activation in endotoxin- and diet-induced atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.110.981365 CrossRefPubMedPubMedCentral

42.

Mehta NN et al (2010) Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes. https://doi.org/10.2337/db09-0367 CrossRefPubMed

43.

Michelsen KS, Wong MH, Shah PK et al (2004) Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.0403249101 CrossRefPubMedPubMedCentral

44.

Shi H et al (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. https://doi.org/10.1172/JCI28898 CrossRefPubMedPubMedCentral

45.

Tsukumo DML, Carvalho-Filho MA, Carvalheira JBC et al (2007) Loss-of-function mutation in toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 56(8):1986–1998CrossRefPubMed

46.

Herieka M, Faraj TA, Erridge C (2016) Reduced dietary intake of pro-inflammatory Toll-like receptor stimulants favourably modifies markers of cardiometabolic risk in healthy men. Nutr Metab Cardiovasc Dis. https://doi.org/10.1016/j.numecd.2015.12.001 CrossRefPubMed

47.

Ghoshal S, Witta J, Zhong J et al (2009) Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res. https://doi.org/10.1194/jlr.M800156-JLR200 CrossRefPubMed

48.

Erridge C, Attina T, Spickett CM, Webb DJ (2007) A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 86:1286–1292CrossRefPubMed

49.

Niebauer J, Volk HD, Kemp M et al (1999) Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353:1838–1842. https://doi.org/10.1016/s0140-6736(98)09286-1 CrossRefPubMed

50.

Cani PD, Possemiers S, Van De Wiele T et al (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. https://doi.org/10.1136/gut.2008.165886 CrossRefPubMed

51.

Amar J, Serino M, Lange C et al (2011) Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia. https://doi.org/10.1007/s00125-011-2329-8 CrossRefPubMed

52.

Burcelin R, Serino M, Chabo C et al (2013) Metagenome and metabolism: the tissue microbiota hypothesis. Diabetes Obes Metab 15(Suppl 3):61–70CrossRefPubMed

53.

Amar J, Chabo C, Waget A et al (2011) Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. Embo Mol Med 3:559–572. https://doi.org/10.1002/emmm.201100159 CrossRefPubMedPubMedCentral

54.

Amar J, Lange C, Payros G et al (2013) Blood microbiota dysbiosis is associated with the onset of cardiovascular events in a large general population: the D.E.S.I.R. study. PLoS ONE 8:e54461. https://doi.org/10.1371/journal.pone.0054461 CrossRefPubMedPubMedCentral

55.

Koeth RA, Wang Z, Levison BS et al (2013) Intestinal microbiota metabolism of L‑carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19:576–585. https://doi.org/10.1038/nm.3145 CrossRefPubMedPubMedCentral

56.

Zhu W, Gregory JC, Org E et al (2016) Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell:1–14. https://doi.org/10.1016/j.cell.2016.02.011 CrossRefPubMedPubMedCentral

57.

Wang Z et al (2015) Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163:1585–1595. https://doi.org/10.1016/j.cell.2015.11.055 CrossRefPubMedPubMedCentral

58.

Organ CL et al (2016) Choline diet and its gut microbe-derived metabolite, trimethylamine N‑oxide, exacerbate pressure overload-induced heart failure. Circ Heart Fail 9:e2314. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002314 CrossRefPubMed

59.

Ferguson JF (2013) Meat-loving microbes: Do steak-eating bacteria promote atherosclerosis? Circ Cardiovasc Genet 6:308–309. https://doi.org/10.1161/CIRCGENETICS.113.000213 CrossRefPubMed

60.

Trøseid M, Ueland T, Hov JR et al (2015) Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure. J Intern Med 277:717–726. https://doi.org/10.1111/joim.12328 CrossRefPubMed

61.

Tang WHW, Wang Z, Fan Y et al (2014) Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol 64:1908–1914. https://doi.org/10.1016/j.jacc.2014.02.617 CrossRefPubMed

62.

Schuett K, Kleber ME, Scharnagl H et al (2017) Trimethylamine-N-oxide and heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 70:3202–3204. https://doi.org/10.1016/j.jacc.2017.10.064 CrossRefPubMed

63.

Shan Z et al (2017) Association between microbiota-dependent metabolite trimethylamine-N-oxide and type 2 diabetes. Am J Clin Nutr. https://doi.org/10.3945/ajcn.117.157107 CrossRefPubMed

64.

Kim MH, Kang SG, Park JH et al (2013) Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Baillieres Clin Gastroenterol 145:396–406. https://doi.org/10.1053/j.gastro.2013.04.056 (e1–10)CrossRef

65.

MacFabe DF et al (2011) Effects of the enteric bacterial metabolic product propionic acid on object-directed behavior, social behavior, cognition, and neuroinflammation in adolescent rats: relevance to autism spectrum disorder. Behav Brain Res 217:47–54. https://doi.org/10.1016/j.bbr.2010.10.005 CrossRefPubMed

66.

Priyadarshini M, Wicksteed B, Schiltz GE et al (2016) SCFA receptors in pancreatic β cells: novel diabetes targets? Trends Endocrinol Metab. https://doi.org/10.1016/j.tem.2016.03.011 CrossRefPubMedPubMedCentral

67.

Kim CH, Park J, Kim M (2014) Gut microbiota-derived short-chain fatty acids, T cells, and inflammation. Immune Netw 14:277–288. https://doi.org/10.4110/in.2014.14.6.277 CrossRefPubMedPubMedCentral

68.

Menzel T et al (2004) Butyrate inhibits leukocyte adhesion to endothelial cells via modulation of VCAM-1. Inflamm Bowel Dis 10:122–128CrossRefPubMed

69.

Aguilar EC, Leonel AJ, Teixeira LG et al (2014) Butyrate impairs atherogenesis by reducing plaque inflammation and vulnerability and decreasing NFκB activation. Nutr Metab Cardiovasc Dis 24:606–613. https://doi.org/10.1016/j.numecd.2014.01.002 CrossRefPubMed

70.

Wu H, Esteve E, Tremaroli V et al (2017) Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 23:850–858. https://doi.org/10.1038/nm.4345 CrossRefPubMed

71.

Arpaia N, Campbell C, Fan X et al (2013) Metabolites produced by commensal bacteria promote peripheral regulatory T‑cell generation. Nature. https://doi.org/10.1038/nature12726 CrossRefPubMedPubMedCentral

72.

Wilck N, Matus MG, Kearney SM et al (2017) Salt-responsive gut commensal modulates TH17 axis and disease. Nature 551:585–589. https://doi.org/10.1038/nature24628 CrossRefPubMedPubMedCentral

73.

Ivanov II et al (2009) Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. https://doi.org/10.1016/j.cell.2009.09.033 CrossRefPubMedPubMedCentral

74.

Cavallari JF, Denou E, Foley KP et al (2016) Different Th17 immunity in gut, liver, and adipose tissues during obesity: the role of diet, genetics, and microbes. Gut Microbes 7:82–89. https://doi.org/10.1080/19490976.2015.1127481 CrossRefPubMedPubMedCentral

75.

Livanos AE, Greiner TU, Vangay P et al (2016) Antibiotic-mediated gut microbiome perturbation accelerates development of type 1 diabetes in mice. Nat Rev Microbiol 1:16140. https://doi.org/10.1038/nmicrobiol.2016.140 CrossRef

76.

Gong F, Wu J, Zhou P et al (2016) Interleukin-22 might act as a double-edged sword in type 2 diabetes and coronary artery disease. Mediators Inflamm 2016:8254797. https://doi.org/10.1155/2016/8254797 CrossRefPubMedPubMedCentral

77.

Abdel-Moneim A, Bakery HH, Allam G (2018) The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus. Biomed Pharmacother 101:287–292. https://doi.org/10.1016/j.biopha.2018.02.103 CrossRefPubMed

78.

Myers JM, Cooper LT, Kem DC et al (2016) Cardiac myosin-Th17 responses promote heart failure in human myocarditis. JCI Insight 1. https://doi.org/10.1172/jci.insight.85851 CrossRefPubMedPubMedCentral

79.

Li J et al (2010) The treg/Th17 imbalance in patients with idiopathic dilated cardiomyopathy. Scand J Immunol 71:298–303. https://doi.org/10.1111/j.1365-3083.2010.02374.x CrossRefPubMed

80.

Ridlon JM, Kang D‑J, Hylemon PB (2006) Bile salt biotransformations by human intestinal bacteria. J Lipid Res. https://doi.org/10.1194/jlr.R500013-JLR200 CrossRefPubMed

81.

Postler TS, Ghosh S (2017) Understanding the Holobiont: How microbial metabolites affect human health and shape the immune system. Cell Metab 26(1):110–130CrossRefPubMedPubMedCentral

82.

Ryan PM, Stanton C, Caplice NM (2017) Bile acids at the cross-roads of gut microbiome-host cardiometabolic interactions. Diabetol Metab Syndr 9:1–12. https://doi.org/10.1186/s13098-017-0299-9 CrossRef

83.

Chávez-Talavera O et al (2017) Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Baillieres Clin Gastroenterol. https://doi.org/10.1053/j.gastro.2017.01.055 CrossRef

84.

Charach G, Argov O, Geiger K et al (2018) Diminished bile acids excretion is a risk factor for coronary artery disease: 20-year follow up and long-term outcome. Therap Adv Gastroenterol 11:1756283X17743420. https://doi.org/10.1177/1756283X17743420 CrossRefPubMed

85.

Jadhav K, Xu Y, Xu Y et al (2018) Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR. Mol Metab 9:131–140. https://doi.org/10.1016/j.molmet.2018.01.005 CrossRefPubMedPubMedCentral

86.

Bozadjieva N, Heppner KM, Seeley RJ (2018) Targeting FXR and FGF19 to treat metabolic diseases-lessons learned from bariatric surgery. Diabetes. https://doi.org/10.2337/dbi17-0007 CrossRefPubMedPubMedCentral

87.

Vrieze A et al (2014) Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol 60:824–831. https://doi.org/10.1016/j.jhep.2013.11.034 CrossRefPubMed

88.

Huffman KM, Shah SH, Stevens RD et al (2009) Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care. https://doi.org/10.2337/dc08-2075 CrossRefPubMedPubMedCentral

89.

Newgard CB, An J, Bain JR et al (2009) A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. https://doi.org/10.1016/j.cmet.2009.02.002 CrossRefPubMedPubMedCentral

90.

Wang TJ et al (2011) Metabolite profiles and the risk of developing diabetes. Nat Med. https://doi.org/10.1038/nm.2307 CrossRefPubMedPubMedCentral

91.

Bhattacharya S, Granger CB, Craig D et al (2014) Validation of the association between a branched chain amino acid metabolite profile and extremes of coronary artery disease in patients referred for cardiac catheterization. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2013.10.036 CrossRefPubMed

92.

Shah SH et al (2012) Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. Am Heart J. https://doi.org/10.1016/j.ahj.2012.02.005 CrossRefPubMedPubMedCentral

93.

Neinast MD, Jang C, Hui S et al (2018) Quantitative analysis of the whole-body metabolic fate of branched-chain amino acids. Cell Metab. https://doi.org/10.1016/j.cmet.2018.10.013 CrossRefPubMedPubMedCentral

94.

Sun H, Olson KC, Gao C et al (2016) Catabolic defect of branched-chain amino acids promotes heart failure. Circulation 133:2038–2049. https://doi.org/10.1161/CIRCULATIONAHA.115.020226 CrossRefPubMedPubMedCentral

95.

Kappel BA et al (2017) Effect of Empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease. Circulation 136:969–972. https://doi.org/10.1161/CIRCULATIONAHA.117.029166 CrossRefPubMed

96.

Lehrke M, Marx N (2011) Cardiovascular effects of incretin-based therapies. Rev Diabet Stud 8:382–391. https://doi.org/10.1900/RDS.2011.8.382 CrossRefPubMedPubMedCentral

97.

Grasset E, Puel A, Charpentier J et al (2017) A specific gut Microbiota Dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism. Cell Metab 25:1075–1090.e5. https://doi.org/10.1016/j.cmet.2017.04.013 CrossRefPubMed

98.

Chimerel C et al (2014) Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep 9:1202–1208. https://doi.org/10.1016/j.celrep.2014.10.032 CrossRefPubMedPubMedCentral

99.

Korpela K, Salonen A, Virta LJ et al (2016) Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. Nat Commun 7:1–8. https://doi.org/10.1038/ncomms10410 CrossRef

100.

Saari A et al (2015) Antibiotic exposure in infancy and risk of being overweight in the first 24 months of life. Pediatr Electron Pages 135:617–626. https://doi.org/10.1542/peds.2014-3407 CrossRef

101.

Surawicz CM, Brandt LJ, Binion DG et al (2013) Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108:478–498. https://doi.org/10.1038/ajg.2013.4 (quiz 499)CrossRefPubMed

102.

Borody TJ, Paramsothy S, Agrawal G (2013) Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep 15:337. https://doi.org/10.1007/s11894-013-0337-1 CrossRefPubMedPubMedCentral

103.

Vrieze A et al (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Baillieres Clin Gastroenterol 143:913–916.e7. https://doi.org/10.1053/j.gastro.2012.06.031 CrossRef

104.

Cani PD, Neyrinck AM, Fava F et al (2007) Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50:2374–2383. https://doi.org/10.1007/s00125-007-0791-0 CrossRefPubMed

Titel: Mikrobiom, Diabetes und Herz: neue Zusammenhänge?
verfasst von: Dr. Dr. med. B. A. Kappel
Prof. Dr. med. M. Lehrke
Publikationsdatum: 07.03.2019
Verlag: Springer Medizin
Schlagwörter: Diabetes und Herz
Diabetes und Herz
Darmmikrobiom
Folgeerkrankungen bei Diabetes mellitus
Typ-2-Diabetes
Erschienen in: Herz / Ausgabe 3/2019
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-019-4791-x

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.

Zu den Praxisempfehlungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Anforderungen an die ambulante Versorgung nach Implantation eines ventrikulären Herzunterstützungssystems

Genistein attenuates pathological cardiac hypertrophy in vivo and in vitro

Clinical implications of cardiovascular outcome trials in type 2 diabetes

Catheter ablation in atrial fibrillation: is there a mortality benefit in patients with diabetes and heart failure?

Heart failure and diabetes: management and open issues

Prognostic information on HCM patients via speckle tracking

Praxisempfehlungen der Deutschen Diabetes Gesellschaft